Research & Clinical Trials
Brii Biosciences ENRICH Data Show 32.4% Retaining HBsAg Loss at 24 Weeks
By News Desk ·
Key takeaways
- In Phase 2b ENRICH, 41.9% of patients achieved HBsAg loss at end of treatment and 32.4% maintained it 24 weeks later.
- ENHANCE Part A1 triple therapy reached 25.5% HBsAg loss at treatment end versus 10.2% with PEG-IFNα monotherapy, with no statistical significance given.
- Brii Biosciences reported a US$276.1 million cash position as of December 31, 2025.
Brii Biosciences reported that 32.4% of patients in its Phase 2b ENRICH study retained HBsAg loss 24 weeks after treatment ended, with 41.9% achieving loss at the end of treatment. TradingView published the results on November 6, 2026. Brii Biosciences is a clinical-stage biopharmaceutical company developing therapies for infectious diseases, chiefly chronic hepatitis B, and central nervous system disorders.
Inside the ENRICH and ENHANCE Results
The ENRICH figures describe an end-of-treatment response rather than a long-term cure rate, and the release reports consistency with ENSURE Cohort 4. In ENHANCE Part A1, triple therapy produced 25.5% HBsAg loss at treatment end against 10.2% for PEG-IFNα monotherapy, and 17.3% against 6.1% at 24 weeks. The release gives no statistical significance for either comparison.
ENHANCE Part A2 recorded 22.5% HBsAg loss at treatment end for the priming regimen. Brii Biosciences said the regimens were generally safe and well tolerated, without adverse-event rates or detailed safety data. The company described the Phase 2b data as adding to earlier Phase 2 studies.
Brii Biosciences' Cash and Funding Record
According to akta.pro company records, Brii Biosciences held a US$276.1 million cash position as of December 31, 2025. The same records list a $260 million Series A/B round at its founding in 2018 and a $155 million Series C completed in March 2021, for total funding of $415 million.
Earlier Hepatitis B Readouts
In July 2026, Investing.com reported mixed end-of-treatment results from two Phase 2b studies, with ENRICH showing HBsAg loss rates of 42.9% and 40.0% against ENHANCE's 25.5%. In May 2026, BioSpace reported that Brii Bio presented final Phase 2 ENSURE results at EASL Congress 2026, showing elebsiran plus PEG-IFNα achieved higher functional cure rates than PEG-IFNα alone. In August 2026, AInvest reported that Brii Biosciences extended its cash runway to 2029 by cutting research and administrative expenses while reporting mixed Phase 2b results for BRII-179.
What Comes After the ENRICH Readout
The release states that further trials would be needed to confirm durable HBsAg loss and to assess safety and efficacy across the regimens.